V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryNRC
Compliance · The complete guide

NRC: US Nuclear Regulatory Commission

In short

A practical guide to authority routing, licensing evidence and record controls for US radiopharmacy and nuclear-medicine manufacturing.

4,154 words · ~19 min read
Radiation safety officer in cleanroom gown with dosimeter badge reviewing a log on a tablet beside a shielded hot cell
NRC licensing shapes how radiopharmacies handle byproduct material.
On this page
  1. 01What NRC means for radiopharmacy operations
  2. 02Agreement States: identify the authority before routing work
  3. 03Materials licensing: build a site-and-activity map
  4. 04Medical use: review the activity, not just the product label
  5. 05NRC vs FDA: separate the review questions
  6. 06Follow the material from scope assessment to closed evidence
  7. 07Connect material events, license versions and review decisions
  8. 08Integrate records without losing identity or review history
  9. 09Worked cases: location changes, activity records and amendments
  10. 10Common failure modes and targeted controls
  11. 11Implementation and review checklist
On this page · 11 sections
  1. 1What NRC means for radiopharmacy operations
  2. 2Agreement States: identify the authority before routing work
  3. 3Materials licensing: build a site-and-activity map
  4. 4Medical use: review the activity, not just the product label
  5. 5NRC vs FDA: separate the review questions
  6. 6Follow the material from scope assessment to closed evidence
  7. 7Connect material events, license versions and review decisions
  8. 8Integrate records without losing identity or review history
  9. 9Worked cases: location changes, activity records and amendments
  10. 10Common failure modes and targeted controls
  11. 11Implementation and review checklist
AI · Explain it for MY operation

How does NRC apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01What NRC means for radiopharmacy operations

NRC is the US Nuclear Regulatory Commission. For US radiopharmacy and nuclear-medicine manufacturing, this article focuses on identifying the relevant authority, evaluating proposed radioactive-material activities, connecting licensing evidence to operations, and reconstructing decisions. Treat receipt, preparation, storage and medical use as separate assessment questions rather than interchangeable activities.

Organize each assessment around four questions:

  • Site: Where will the work occur, and which authority should review it?
  • Material: What radioactive material is involved, and how is it identified?
  • Intended activity: What exactly is proposed, including any change from the existing operation?
  • Decision owner: Who evaluates the scope, resolves uncertainty and records the decision?

Use a reference register to keep the basis for each decision explicit. Distinguish:

  • Binding regulatory text: identify the applicable jurisdiction, provision and scope.
  • Official agency guidance or program information: retain its advisory or explanatory status.
  • Local operating practice: label site procedures and review conventions as local choices.
  • Proposed software controls: describe intended record handling separately from legal obligations.

Connect unresolved applicability questions to a quality risk register, and use production context tagging to associate operational records with the assessed site, material and activity.

The controls described here are recommended record and review designs, not universal legal requirements. Software support is a separate design layer; it does not establish authorization or replace human review, approval or release decisions.

02Agreement States: identify the authority before routing work

For US radiopharmacy operations involving byproduct materials, the NRC Agreement State Program explains that NRC relinquishes portions of its licensing and regulatory authority over those materials to states. For US byproduct-material operations, that official program explanation describes the transfer mechanism as an agreement signed by the state's governor and the Commission's chairman. This is an official explanation of the authority-transfer model, not a site-specific authorization.

Build a site-level authority assessment

As an operational practice, treat the issuing authority as a reviewed attribute of the operating scope. Do not inherit it from a corporate address, a sister facility's license or the sending site's arrangements during technology transfer. A useful assessment records:

FieldWhat to capture
Site addressPhysical location of the proposed work.
Operating legal entityEntity responsible for the operation.
Material categoryCategory relevant to the authority assessment.
Intended activityWork proposed at that location.
Authority contactRelevant licensing office and contact details.
Agreement-scope assessmentReasoning connecting the material and activity to the authority.
Supporting referenceCurrent reference and any clarifying correspondence.
ReviewerPerson reviewing the conclusion and unresolved questions.

For a new location, use the current program directory and relevant authority contacts rather than a static state-count summary. Record unresolved scope questions explicitly and assign someone to resolve them before routing the licensing work. These are recommended assessment fields and workflow controls, not a prescribed regulatory form.

Keep two decisions separate: identifying the authority for the operating scope, then assessing whether a particular license document addresses the proposed activity. Describe that activity concretely enough to connect it to the planned operation step. Record the authority conclusion and its basis as an input to the later license review, not as a substitute for it.

03Materials licensing: build a site-and-activity map

For US radiopharmacy byproduct-material licensing questions, check the current text of 10 CFR Part 30 and relevant state rules for scope. Start the assessment with the actual site, operating entity, material and proposed activity—not the product name alone.

The applicability register below is a proposed review tool, not a statement of legal permissions or required record fields. Each row remains conditional until a reviewer resolves its scope and documents the basis. Replace pending entries with specific document identifiers and decisions.

JurisdictionProduct or operationQuestion to resolveGoverning documentExact provisionLicense referenceReviewerDecision status
US; NRC authority assessmentRadiopharmaceutical manufacturingDoes NRC authority apply to this site, material and activity?Candidate: Part 30; site authorizationTo identifyTo matchAssigned licensing reviewerPending scope review
US; Agreement State assessmentRadiopharmaceutical manufacturingDoes state authority cover this site, material and activity?Candidate: relevant state rules; site authorizationTo identifyTo matchAssigned licensing reviewerPending scope review
US; authority unresolvedMedical-use operationsWhich framework applies to the described use?Candidate: Part 35 or relevant state rules; authorizationTo identifyTo matchAssigned medical-use reviewerPending activity review
US; authority unresolvedCombined manufacturing and medical useHow does authorization address each activity at this site?Candidate: applicable federal/state rules; authorizationsPer activityPer activityJoint activity reviewersPending combined review

Describe the proposed work in operational terms, linking each operation where useful. For example, distinguish raw material receipt from subsequent processing. Keep that factual description separate from the reviewer's interpretation of authorization text. Preserve the passage relied upon, its document location, the rationale and any unresolved question; a conclusion without its basis is difficult to reassess.

Recommended license-document index: issuer, license number, named entity, site references, document version, effective date, amendments, supersession relationship and original-document location. Link each register decision to the particular document version reviewed, rather than only to a folder containing current documents.

For this proposed workflow, trigger reassessment when the location, operating entity, material or activity changes, or when a new license-document version arrives. Route the affected rows back to the named reviewer; retain the earlier decision and record whether the revised assessment changes the planned work.

04Medical use: review the activity, not just the product label

For US nuclear-medicine medical-use activities, check the current text of 10 CFR Part 35 and relevant state rules for scope. A product’s intended-use description is an input to that assessment, not a concluded legal classification. Record the review decision and its basis rather than treating a department name as the answer.

As an operational practice, build an activity map with separate entries for material receipt, preparation, manufacturing, testing, dispatch and any patient-facing use performed at the facility. Describe what actually happens at each operation step; avoid collapsing distinct activities into a single radiopharmacy label. The map supports review—it does not itself establish authorization.

  • Where does the activity occur, and which legal entity performs it?
  • What material is involved, and what is done with it?
  • Which license, amendment or other authorization evidence is relevant to the assessment?
  • Who owns the assessment, and who resolves uncertainty before the activity proceeds?
  • What decision was reached, on what basis, and which changes would trigger reassessment?

For mixed operations, assign an assessment owner to each activity and define the record handoff between manufacturing and medical-use teams: sender, recipient, material identifier, activity reference and review status. Use production context tagging to preserve the manufacturing context without substituting it for the scope decision. Keep clinical records outside this proposed manufacturing evidence model unless the reviewed activity and a defined information need justify a connection. Where a connection is justified, specify the information needed rather than copying the entire clinical record.

05NRC vs FDA: separate the review questions

For radiopharmacy operations, a useful review design separates materials authorization from product disposition: does the proposed material activity fit the documented authorization assessment, and is the resulting product acceptable for its intended disposition? Document each decision against its own supporting evidence. Neither decision should stand in for the other. Use the authority-routing explanation above when identifying the materials regulator.

The comparison below is an operational model, not statutory definitions or prescribed job assignments. Decision owners are suggested site roles; confirm their responsibilities locally.

Term or recordOperational questionEvidence to inspectDesignated decision owner
NRC: agency identityWhich agency does this reference identify?Agency correspondence and document issuerRegulatory lead
Agreement State route: authority assessmentWhich authority should receive this activity question?Site-and-activity authority assessmentMaterials regulatory lead
Materials license: authorization documentDoes the assessed scope cover this proposed activity?License version, conditions and amendmentsDesignated licensing reviewer
Manufacturing batch record: production evidenceWhat happened during manufacture?Batch record, results and deviationsProduction reviewer
Product-quality disposition: separate review decisionWhat disposition does the quality evidence support?Specifications, results and resolved investigationsDesignated quality approver

For US radiopharmaceutical products, check current product- and activity-specific rules before assigning an FDA review pathway or concluding which obligations apply. A materials-license reference alone is not a useful basis for that assessment.

Recommended record design uses separate status fields for authority assessment, material-event acceptance and product-quality disposition, rather than one compliance-approved status. Link each status to its evidence, reviewer, decision date and unresolved questions. Route changes affecting those decisions through change control. Software can organize the records; designated humans retain review, approval and release decisions.

06Follow the material from scope assessment to closed evidence

For radiopharmacy operations, the following is a proposed site workflow, not a statement of NRC recordkeeping requirements. Its purpose is to connect material movements with review decisions while keeping responsibility visible at each handoff. Apply it through the site's documented responsibilities.

  1. Define operating scope. Identify the site, location, material and intended activity before routing work. Give the assessment a retrievable reference so receiving and production teams can connect subsequent events to the scope actually reviewed.
  2. Review authority and license evidence. Assign a designated reviewer to connect the scope assessment with the relevant authority, license version and supporting decision. Record unresolved applicability questions with a named owner and next action rather than treating a completed checklist as authorization.
  3. Receive material. In the raw-material receipt record, associate supplier identity and supplier lot reference with the receiving site's lot identifier, receiving event and relevant operating-scope assessment. Assign material-handling ownership for checking the physical receipt against that record and routing discrepancies.
  4. Record operations. Connect transfers, uses, returns and disposition events to their material lot and supporting records in the process event log. For each activity observation, preserve the recorded value, unit, reference time and time-zone context alongside the original observation. Keep a physical event distinct from a later correction to its documentation; identify what was corrected without implying that the material moved again.
  5. Resolve exceptions. Use an unresolved state with an explicit reason, owner and next action. Route technical interpretation to the designated technical reviewer, production-documentation issues to the documentation owner, and product-quality questions to the quality reviewer. Use the site's responsibility assignments rather than assuming one role owns every decision.
  6. Approve disposition. Move an event to ready for review only when the assigned preparer has assembled its supporting references and identified any remaining questions. The designated human reviewer decides whether to approve the proposed disposition or return it for further work. Link related material-review decisions where useful.
  7. Close the evidence set. Close an event only after its designated review is complete and its evidence references are retrievable. Record who completed the review and its outcome. A successful data transfer demonstrates delivery, not review completion; missing attachments or an unanswered review question should remain visible rather than disappear behind a closed status.

Workflow: Scope → Authority review → Receipt → Operations → Exception resolution → Disposition approval → Evidence closure

Material and Review Lifecycle
  1. 1
    Define scopeIdentify the site, material and intended activity.
  2. 2
    Review authorityRecord the authority assessment and license version.
  3. 3
    Receive materialCapture lot identity, units and reference time.
  4. 4
    Track operationsConnect material movements with their supporting records.
  5. 5
    Resolve exceptionsReconcile discrepancies before the designated reviewer decides.
  6. 6
    Approve dispositionKeep technical review and product-quality decisions distinct.
  7. 7
    Close evidenceConfirm retrievability and resolve outstanding review actions.
A proposed operating sequence; each decision remains with the designated human reviewer.

07Connect material events, license versions and review decisions

For US radiopharmacy radiation-protection records, check the current text of 10 CFR Part 20 and relevant state rules for scope. Use the licensing and medical-use references above for their respective applicability reviews. The structure below is a proposed implementation model, not a statement of legal record obligations.

Connect the authority assessment to the license version considered for the site and activity. Link each material event to its material lot, supporting evidence records and human review decision. A process event log can provide the event sequence, but chronology alone does not explain the authorization basis or review outcome.

Have each review decision reference the specific license version actually considered, with reviewer identity, decision time and rationale. A link that always displays the latest license can conceal what the reviewer saw. Keep the historical reference even when a later amendment prompts reassessment; record that reassessment as a separate decision.

  • Original observations: preserve the source record, observation time, originator and measurement context.
  • Calculated or transformed values: identify inputs, units, method and method version without replacing the original observation.
  • Explanatory annotations: attach interpretation or correction rationale while keeping authorship and timing visible.
  • Approval decisions: record the human disposition separately from the evidence being assessed.

Treat activity measurements, contamination observations and dose assessments as distinct record types, not interchangeable numeric fields. Preserve each type’s quantity, units, method and context so a shared display cannot erase its meaning.

Maintain a retention-basis register linking each record class to its reviewed authority, exact provision or document basis, scope, responsible owner and review status. Distinguish binding requirements from guidance and internal policy. Do not adopt a generic retention deadline; resolve the basis for each class before setting its disposition rule.

Test retrieval by selecting a material event and tracing it to its source record, authority assessment, license version, exception history and reviewer decision. Use an audit trail review workflow to examine changes and follow-up decisions rather than merely confirming that documents exist.

Proposed implementation model — field names, not regulatory terminology: authority_assessment_id → license_version_id material_event_id → material_lot_id + evidence_record_id evidence_record_id → source_record_id + record_type review_decision_id → material_event_id + authority_assessment_id + license_version_id + exception_history_id

Records and Decision Relationships

Authority Assessment

Defines the evaluated operating scope.

  • scope_id
  • site_id
  • authority_name
  • material_type
  • intended_activity
  • assessment_status

License Version

Preserves the authorization document's identity.

  • license_version_id
  • scope_id
  • license_number
  • version_ref
  • effective_date
  • document_ref

Material Lot

Carries activity and timing context.

  • lot_id
  • radionuclide
  • activity_value
  • activity_unit
  • reference_time
  • time_zone

Material Event

Links each movement to evidence.

  • event_id
  • lot_id
  • scope_id
  • event_type
  • event_time
  • source_event_id

Evidence Record

Locates the preserved original record.

  • record_id
  • event_id
  • record_type
  • source_system
  • original_ref
  • retention_basis_ref

Review decision

Attributes decisions to human reviewers.

  • decision_id
  • event_id
  • license_version_id
  • reviewer_id
  • decision_time
  • outcome
A proposed evidence model, not a universal legal record specification.

08Integrate records without losing identity or review history

For radiopharmacy operations, the following is a proposed integration design, not a statement of NRC recordkeeping requirements. Connect systems through references to original records rather than treating every imported copy as a new material event.

Assign ownership explicitly: inventory owns material-lot identifiers and stock transactions; manufacturing owns batch identifiers and execution records; laboratory or instrument systems own observation identifiers and original measurements; document management owns controlled-document identifiers and versions. Each originating system owns its source-event identifiers. Maintain cross-system mappings using production context tagging, without replacing native identifiers.

Define an interface contract containing source-system identity, stable source-event identifier, lot mapping, measurement context, event time, ingestion time and reconciliation status. For radioactivity observations, measurement context should include units, instrument identity and any reference time used. Distinguish when the observation occurred from when the receiving system acquired it; MES–historian integration benefits from that same distinction.

  • Duplicate message: match source-system identity and source-event identifier, compare content, and document the reconciliation decision. Do not create another material event merely because transmission was repeated.
  • Late or corrected observation: link it to the original event, preserve the earlier observation, and explicitly assess whether any completed review needs reopening through the audit trail review workflow.
  • Connection loss: preserve the original observation at its source and queue the affected record for reconciliation. Resolve gaps, duplicates and mapping exceptions before normal processing of that record resumes.

Limit proposed software support to record linking, status visibility and exception routing. Authorization, technical acceptance of imported records and product release remain human decisions. Keep technical acceptance of an import separate from acceptance of the material or product it describes.

09Worked cases: location changes, activity records and amendments

These cases illustrate proposed operational controls, not legal determinations. Each separates the unresolved question from the evidence and human decision needed to close it.

Location change: assess the destination

Assumption: A US radiopharmacy plans to move radioactive material to a different operating location; the receiving location’s authority assessment remains unresolved.

Relevant evidence: Open a destination scope record identifying the receiving address, material and intended activity. Request the destination-specific licensing documents and authority references needed to resolve the assessment, and assign a designated materials-authorization reviewer.

Decision path: Propose an operational hold on the affected movement pending that review. Another site’s assessment is context, not the destination’s answer.

Recorded outcome: Capture the authority decision and its supporting reference before the designated reviewer authorizes the affected workflow to resume. Link that authorization to the movement’s process event log.

Activity record: reconcile units and reference times

Assumption: An incoming observation uses millicuries; the inventory record uses megabecquerels. Their reference times differ.

Relevant evidence: Preserve both original observations, units, timestamps, radionuclide identity and source records. Flag both the unit mismatch and the time-basis mismatch.

Decision path: Have the technical reviewer separate unit conversion from time-basis reconciliation. Retain the conversion basis, selected comparison time and any decay-correction calculation, including its inputs and method.

Recorded outcome: Link the reviewed comparison to both originals. If the difference remains unexplained, record an unresolved discrepancy rather than presenting it as physical material loss.

Amendment: reassess the open decision

Assumption: A license-document version changes while a dispatch review is open.

Relevant evidence: Preserve the earlier assessment and its document version. Link the replacement document and identify the dispatch decision potentially affected through change control.

Decision path: Route that decision to the designated reviewer for reassessment. Do not assume that a replacement document either permits or prohibits the pending dispatch.

Recorded outcome: Identify the version actually considered, the reviewer’s rationale and the resulting disposition. Retain the earlier decision without overwriting it or presuming the amendment’s legal effect.

10Common failure modes and targeted controls

Use these proposed operational controls for radiopharmacy records; they are practice recommendations, not statements of binding requirements or official guidance. Connect receiving checks to raw material receipt and reference repairs to document control.

Observable symptomLikely information failureProposed controlEvidence that the control operated
Supplier name differs between receipt and supporting document.Trading name, legal entity or site identity has not been reconciled.Preserve the incoming document, compare named entities and assign an owner for the identity-resolution decision.Recorded comparison, supporting references and named reviewer’s decision.
A review’s document reference no longer opens.The reference or access route has broken.Restore access to the preserved original; confirm the retrieved document is the version cited by the review.Successful retrieval check and recorded version match.
The same material appears under inconsistent free-text names.Supplier descriptions lack a reviewed identity mapping.Use a reviewed material identifier while retaining the supplier’s original description.Reviewed mapping linking the identifier to the original description.
An exception remains in an inbox without follow-up.Ownership and workflow status are missing.Assign a named role, next action and review status in a tracked record.Assignment, action history and documented disposition.

Treat a failed data check as an investigation trigger, not a concluded regulatory violation. Investigate underlying facts before assigning final disposition. Apply the earlier unit, version and duplicate-message checks where relevant.

11Implementation and review checklist

Use this practical review exercise to test whether the radiopharmacy’s evidence is usable, not to declare regulatory compliance.

  • Confirm a named operating-scope owner and a documented, reviewed authority route.
  • Check that license documents and amendments are indexed and their applicable versions identifiable.
  • Confirm that the distinct review statuses described above remain visible, with reviewers and decision dates.
  • Check relationships between material events, supporting documents, observations and decisions.
  • Assign exception ownership and confirm that retention decisions have a recorded basis and owner; use the register structure in the records section.

Select a completed material event. Reconstruct what happened, which document versions informed the decision, who reviewed it and where the original evidence is retained. Include the relevant audit trail review workflow, rather than checking only the final status.

In a controlled test, introduce a duplicate message, a missing attachment and a corrected observation. Check that recovery preserves identity and history, exposes missing evidence and routes unresolved exceptions to an owner through the appropriate deviation process. Record unresolved applicability questions as assigned review actions, not a completed assessment.

Acceptance criterion: another qualified reviewer can follow the evidence and understand the decision without relying on the original operator’s memory.

Frequently asked questions

Q.Does an authority assessment for one radiopharmacy site settle the route for every site in the same company?+

No—treat it as a starting point, not a company-wide conclusion. For US radiopharmacies handling byproduct material, NRC’s Agreement State Program explanation describes states assuming portions of NRC licensing and regulatory authority. As an operational practice, assess each location’s legal entity, activities, materials and proposed licensing route separately. Record unresolved jurisdiction questions in the quality risk register, and carry the site-specific assessment into technology transfer rather than copying another facility’s conclusion.

Q.What should a receiving team do when a supplier's license document and purchase order name different entities?+

As a receiving-control practice, pause acceptance into usable inventory and refer the mismatch to the designated radiation-safety or licensing reviewer. Compare the named licensee, shipping location, ordering entity and any documented trading-name relationship; a similar name alone is not a reliable match. Keep the discrepancy attached to the receiving record, with material in a defined quarantine status under appropriate storage controls. Record who resolved the identity question and the basis for acceptance or rejection.

Q.How can a batch record reference radioactive-material evidence without duplicating the entire licensing file?+

Use a controlled reference that identifies the document, revision or amendment, applicable location and relevant material or activity. As a record-design practice, the batch record can retain the transaction-specific check, reviewer and decision while pointing to the controlled licensing file for supporting detail. Make the reference retrievable after later amendments, rather than linking only to the latest document. Consistent production context tagging helps associate the evidence with the correct batch, material event and site.

Q.Why should an activity observation include its unit, reference time and time zone?+

An activity value is interpreted against both a measurement scale and a time basis. Without the unit, a reviewer cannot reliably compare values; without the reference time and time zone, observations from different systems may appear comparable when they are not. As a measurement-record practice, distinguish the measurement timestamp from the time to which a value has been corrected. Record whether the value is observed or calculated, and link any decay correction to its inputs and method.

Q.How should a late instrument result be handled after the associated material event has been reviewed?+

Preserve the original event and review, then attach the late result with its measurement time, receipt time and reason for delayed availability. As a review practice, assess whether it changes the earlier conclusion, affects related material, or calls for a deviation assessment. Do not silently replace the reviewed value or backdate the result. Use an audit trail review workflow to connect the new information, impact assessment and any revised human decision without erasing the earlier decision.

Q.How can a retention schedule distinguish regulatory provisions, license-document references and local policy?+

As a records-management practice for a US radiopharmacy, give each record class separate fields for the applicable regulatory provision, license-document reference and local policy basis. Check the current applicable 10 CFR or state text before assigning a regulatory retention period. Record the retention trigger, responsible owner and any preservation hold separately. In document control, distinguish an internally selected period from a legally prescribed period, and record how overlapping bases were reconciled rather than labelling every entry an NRC requirement.

Q.What should be reviewed when a manufacturing facility adds a patient-facing medical-use activity?+

Treat the proposal as a change in activity, not merely an additional manufacturing step. As a planning practice, use change control to map the proposed patient service, locations, materials, responsible personnel, equipment and records. Ask the licensing reviewer to assess the authorization route before implementation. Separately assess the handoff between manufacturing disposition and patient-use decisions, including scheduling, identification and escalation responsibilities. Keep the resulting actions assigned to named owners rather than assuming the existing manufacturing assessment covers the new service.

Q.How can a reviewer reconstruct a dispatch decision after the license document has been superseded?+

As a historical-review practice, retain the document version used for the dispatch check alongside its effective status at that time. Connect it to the recipient, destination, material description, dispatch event and reviewer’s recorded reasoning. The electronic release record should distinguish the historical decision from any later reassessment. Preserve subsequent amendments as separate versions so a reviewer can establish what information supported dispatch, what changed afterward, and whether someone evaluated the change’s effect on the earlier decision.

Primary sources

  • NRC Agreement State Program
Software that covers NRC
V5 Ultimate Nuclear
10 CFR 50 Appendix B eighteen criteria, NQA-1 Part I / II compliance, 10 CFR Part 21 defect and non-conformance reporting, ASME…
V5 Ultimate Radiopharmaceutical Manufacturing
Time-stamped batch record for short production windows, QC results tracked as available or pending, human release review and Part…
V5 Ultimate Training Management
Role-based curricula, read-and-understood against controlled SOPs and competency records, with retraining assigned by your team…

Explore this topic

NRC sits inside 2 overlapping topic clusters in our glossary. Every neighbour is one click away.

Radiopharmaceuticals
8 related entries

PET / SPECT GMP, decay math, NRC controls and conditional release.

21 CFR 212RG 1.86Half-LifeDecay CorrectionALARAConditional ReleaseQP ReleaseUSP
Global Regulators
5 related entries

National competent authorities that inspect manufacturers outside the US and EU.

MHRA (UK)PMDA (Japan)TGA (Australia)ANVISA (Brazil)NMPA (China)
Talk to us about NRC

Want to see how NRC could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
Radiopharma
Inside V5
  • → Score your compliance gap — then download the validation pack.
  • → Document control — one version in force, every change signed and explained.
  • → QMS — quality records next to the work they concern.
Regulatory anchors
  • 10 CFR Part 20
  • 10 CFR Part 35
  • 10 CFR Part 71
Related terms
  • → ALARA
  • → 21 CFR 212
  • → RG 1.86
  • → Half-Life
  • → Decay Correction
  • → Conditional Release
  • → QP Release
  • → USP
  • → MHRA (UK)
  • → PMDA (Japan)
  • → TGA (Australia)
  • → ANVISA (Brazil)
  • → NMPA (China)

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC